阿片类过敏交叉反应:在三种阿片类药物中进行的回顾性研究
Ali Khalaf1, Matthew Lane1, Jennifer Meyer Reid1
1Lexington VA Health Care System, Lexington, Kentucky, USA.
Journal of pain & palliative care pharmacotherapy
|January 2, 2025
概括
真正的阿片类过敏很少见. 这项研究没有发现阿片类之间的交叉反应性,在再暴露时显示100%的耐受性,这可能有助于管理先前有阿片类药物不良反应 (ADR) 的患者.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 通过IgE介导的阿片类药物过敏 (真正的过敏) 是罕见的;大多数反应是副作用或伪过敏.
- 由于免疫媒介阿片类过敏的罕见性,阿片类之间的交叉反应性存在有限的文献.
- 了解交叉反应性对于管理已记录阿片类药物不良反应 (ADRs) 的患者至关重要.
研究的目的:
- 为了确定记录了阿片类药物过敏或ADRs的患者之间的交叉反应率和耐受性.
- 评估自然,半合成和合成阿片类阿片类药物随后暴露的结果.
- 为了评估阿片类药物交叉反应在一个大患者队列与阿片类药物ADRs的历史.
主要方法:
- 在一家退伍军人事务医院10年来对1507名经过记录的阿片类药物过敏或ADR患者进行了回顾性研究.
- 根据他们之前的过敏/ADR的阿片类药物类别,患者被分为三个队列.
- 随后的阿片类药物暴露在每个队列的三个阿片类药物类别中进行了评估.
主要成果:
- 在任何阿片类药物类别中都没有观察到交叉反应.
- 在所有研究组中发现了100%的再暴露耐受率.
- 这表明,在先前的ADR后,在重新挑战患者时,他们可能会耐受不同类型的阿片类药物.
结论:
- 对阿片类药物过敏和交叉反应不常见.
- 患有阿片类过敏或ADR病史的患者可能可以耐受不同药物类别的阿片类药物.
- 这些发现支持了对使用替代阿片类药物类别的信心增加,对于那些有记录的阿片类过敏或ADRs的患者.
关键词:
在阿片类药物中,阿片类药物过敏是一种过敏.过敏反应是一种过敏反应.交叉反应性 交叉反应性过敏性过敏性过敏性自然的自然的自然的自然的自然伪过敏是一种伪过敏.一个半合成的半合成.这是一种合成的合成物质.这是一个宽容的宽容度.更多相关视频
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
9.5K
07:23Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
33.2K
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
163
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
163
Opioid Receptors: Overview
305
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
305
Opioid Analgesics: Morphine and Other Natural Cogeners
132
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
132
Analgesia and Pain Management
390
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
390
Cross-reactivity
30.9K
Overview
30.9K
Allergic Drug Reactions
783
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
783
